Strategic Financing Advisory in Life Sciences
R&D-focused companies are in the DNA of FCF. Life Sciences is therefore a natural fit as one of our focus areas. Companies in this sector have unique financing requirements, which need to be addressed individually. For this reason, we have formed a team of highly specialized industry and finance experts to develop and execute the best individualized financing strategies for our Healthcare clients. The combined experience and skill set allows us to tackle every angle in the translation of a great technology into a sound financing story.
We work with innovative European Life Sciences companies with cutting-edge technologies from sectors such as:
- Biotechnoloy
- Medical Technology
- Health Technology (IT)
We thrive to address all aspects of the financing challenges, that companies face from the seed to the commercialisation phase. We consider the long-term financing strategy as an important success factor, rather than focusing only on the next financing round. Part of this approach is to explore financing options on a regional and international scale and the combination of all available financing instruments:
- Venture Capital
- Equity-Linked Structures
- Growth / Venture Debt
- Off-Balance Financing
- Licensing
FACTS & FIGURES
European Life Sciences team specialised in pre-IPO financing
WHAT WE DO
At FCF Life Sciences, we develop bespoke financing strategies and support our clients throughout the entire fundraising process and beyond:
Industry Expertise
- Technology Assessment
- Finetuning of Equity Story
- Pre Due-Diligence
- Science-driven Deal Selection
Finance Expertise
- Process Management
- Investor Relations
- Intelligent Market Monitoring
- Efficient Investor Communications
- Technology Assessment
- Finetuning of Equity Story
- Pre Due-Diligence
- Science-driven Deal Selection
- Process Management
- Investor Relations
- Intelligent Market Monitoring
- Efficient Investor Communications
FOCUS AREAS
- Actively managed global investor network to >1,500 investor
- Highly customized investor approach based on a proprietary investor data base
- Focus on seed to crossover rounds
- Most successful advisor in Europe
- Direct access to the European Investment Bank with >EUR 200m raised
- Access to more than 70 Growth / Venture Debt Providers (executive level)
- Joint Venture with YAFO Capital (Shanghai) Ltd.
- Specialist in fundraising, licensing and M&A transactions in the Asian market
- Access to >500 financial and strategic investors
- Collaboration with BioScience Valuation GmbH
- Leader in evidence-based commercial, R&D, and economic evaluations
- Valuable support for investment and partnering decisions
TEAM
We have built the largest venture stage dedicated team with industry and finance backgrounds in Europe:
Industry Expertise
Finance Expertise
Dr. Alexandra Goll
Advisor – Venture Capital
Dr. Axel Polack
Advisor – Science & Technology
Enno Spillner
Advisor – Capital Markets
Claus Schalper
Advisor – Corporate Affairs
Dr. Joachim M. Greuel
Advisor – Valuations
Prof. Dr. Horst Domdey
Advisor – Science & Technology
Arno Fuchs
Chief Executive Officer
Dr. Mathias Schott
Advisor Life Sciences
Johannes Link
Life Sciences Banking – Europe
Sean Jiang, CFA
Life Sciences Banking – China
We have built the largest venture stage dedicated team with industry and finance backgrounds in Europe:
GLOBAL NETWORK
We maintain trusted relationships to leading institutional and strategic Healthcare investors as well as family offices in Europe, USA and Asia. Supported by our US and Asian partners, we can approach the right investors depending on our client’s situation. We can rely on a deep network to Life Sciences specialists (e.g. legal, valuation, licensing and IPO investment banks in the USA and Europe) to execute a seamless 360-degree long-term financing strategy. Our goal is to create value by implementing the best financing options for our clients.
| FCF Partner (New York): |
|---|
|
 |
FCF Life Sciences (Munich): |
|---|---|
|
 |
BioScience Valuation (Garmisch): |
|---|---|
|
 |
DACH ADVISORY (Dubai): |
|---|---|
|
 |
YAFO Capital (Shanghai): |
|---|---|
|
| FCF Partner (New York): |
|---|
|
|
|---|
| FCF Life Sciences (Munich): |
|
|
|---|
| BioScience Valuation (Garmisch): |
|
|
|---|
| DACH ADVISORY (Dubai): |
|
|
|---|
| YAFO Capital (Shanghai): |
|
SELECTED TRANSACTIONS
numares AG
February 2022
€ 20 million
Precisis AG
September 2021
€ 20 million
Immunic AG
October 2020
€ 25 million
Vasopharm GmbH
July 2019
[amount confidential]
AMW GmbH
November 2017
€ 25 million
numares AG
February 2022
€ 20 million
UPCOMING EVENT
| ACCESS CHINA Biotech Forum |
Winter Showcase 2022 January 4th to 13th (Online & San Francisco) |
MARKET INTELLIGENCE
We dedicate a fair amount of our resources to market monitoring, in order to derive market intelligence on life sciences companies, investors and capital market trends. We share our findings in various ways:
To hear from us on the latest market updates, please sign-up here:
Venture Capital Sentiment
Based on our market monitoring, we estimate the current monthly venture capital sentiment of the European biotechnology, medical technology and health technology sub-sectors:
April 2023:
Biotechnology
Medical Technology
Health Technology
Biotechnology
Medical Technology
Health Technology
Insights
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
Venture capital funding in 2022 significantly decreased compared to 2021
The ever-increasing venture capital funding for European life sciences companies halted in 2022. With a roughly EUR 9.6bn volume, the overall financing for European life sciences companies in 2022 decreased significantly compared to 2021 (EUR 13.6bn) by 28%. While in the first quarter, funding volumes roughly matched, from April onwards,
European VC life sciences funding continues to decline
In 2022, the venture capital funding for life sciences in Europe continues to weaken, further widening the gap to 2021 (EUR 9.4bn vs. EUR 6.5bn). The cumulative financing volume in August 2022 falls by more than -31% compared to August 2021. The cumulative number of closed deals in 2022 started
US year-to-date funding volume now below previous year’s level
After an exceptional year 2021 for venture capital funding in the US Biotech-sector, aggregated financing volumes in 2022 are for the first time lower than in 2021. During the last months funding volumes have declined significantly. Especially in June, funding volumes were almost three times as high compared August. Excluding
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
Life Sciences Venture Capital Monitor – Europe 04/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
FCF Biotech Venture Capital Monitor – USA 03/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 03/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Life Sciences Venture Capital Monitor – Europe 03/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 03/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
Life Sciences Venture Capital Monitor – Europe 02/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 02/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
Life Sciences Venture Capital Monitor – Europe 01/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 01/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
